Summary: A longitudinal study from researchers at UT Health San Antonio links higher midlife cortisol levels with greater brain amyloid accumulation—a hallmark of Alzheimer’s disease—specifically among post‑menopausal women. Tracking 305 cognitively healthy adults over about 15 years, the team found that elevated cortisol in midlife predicted later amyloid deposition in women who had experienced menopause, while no similar association emerged for men or for tau pathology.
The results point to an interaction between stress hormones and hormonal changes after menopause that may increase vulnerability to Alzheimer’s pathology. They also highlight the potential value of early stress reduction and consideration of hormonal status when targeting Alzheimer’s risk.
Key facts
- Sex- and menopause-specific risk: High midlife cortisol predicted later amyloid accumulation only in post‑menopausal women.
- Pathology-specific link: The association was observed with amyloid PET measures but not with tau PET burden.
- Prevention implications: Findings suggest stress management and hormone‑sensitive strategies could be explored to reduce Alzheimer’s risk in vulnerable women.
Source: UT Health San Antonio
Can stress increase Alzheimer’s risk? Evidence from the Framingham Heart Study suggests it may, at least for women after menopause. The investigators examined data from 305 cognitively unimpaired participants enrolled in the third generation cohort of the Framingham Heart Study. Baseline serum cortisol was measured in midlife, and amyloid and tau brain burden were assessed roughly 15 years later using PET imaging.
By comparing midlife cortisol concentrations with subsequent PET markers approximately 15 years later, the researchers were able to evaluate cortisol as a potential preclinical biomarker for Alzheimer’s disease while participants remained cognitively normal. The study adjusted for key confounders, including APOE4 status, and used multivariable regression to isolate the relationship between cortisol and later imaging biomarkers.
The main finding was a sex‑specific association: elevated midlife cortisol correlated with increased amyloid deposition in brain regions such as the posterior cingulate, precuneus, and lateral frontal cortex among post‑menopausal women (p < 0.05). No comparable associations appeared in men, nor were cortisol levels linked to tau PET burden in either sex.
“The results highlight the importance of identifying early risk factors when biomarkers are detectable but cognitive impairment is absent,” said Arash Salardini, MD, associate professor of cognitive and behavioral neurology with the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio, and the study’s first author. He noted that continuing longitudinal follow‑up will be essential to see whether early amyloid differences predict later clinical decline and to clarify cortisol’s causal role.
Senior author Sudha Seshadri, founding director of the Biggs Institute, emphasized that considering sex and hormonal status matters when studying Alzheimer’s pathogenesis. “Our findings suggest that stress reduction and hormonal interventions may hold promise for Alzheimer’s prevention, especially in at‑risk women,” she said.
Why focus on cortisol? Cortisol is a central stress hormone involved in cellular homeostasis and the body’s stress response. Prior genetic and observational studies have linked glucocorticoid signaling pathways and higher circulating cortisol with increased Alzheimer’s susceptibility, but results have been inconsistent. This study addresses those gaps by evaluating cortisol measured in midlife and relating it to imaging biomarkers a decade and a half later, allowing assessment during a preclinical stage when interventions might be most effective.
The investigators also considered the protective effects of sex hormones—estrogen and testosterone—which can mitigate cortisol’s harmful effects on neural tissue. Because estrogen levels decline at menopause, the team hypothesized that cortisol’s impact on Alzheimer’s pathology would be stronger in post‑menopausal women. Their results support this hypothesis, showing an interaction between menopausal status and cortisol‑related amyloid accumulation.
Although the study identifies an important association, it does not prove that cortisol causes Alzheimer’s disease. The authors call for further longitudinal monitoring of this cohort and for studies testing whether interventions that lower chronic stress or address hormonal changes can reduce amyloid accumulation and subsequent cognitive decline.
About this Alzheimer’s disease research news
Author: Steven Lee
Source: UT Health San Antonio
Contact: Steven Lee – UT Health San Antonio
Image: Image credited to Neuroscience News
Original research (open access): “Elevated serum cortisol associated with early‑detected increase of brain amyloid deposition in Alzheimer’s disease imaging biomarkers among menopausal women: The Framingham Heart Study” by Arash Salardini et al., published in Alzheimer’s & Dementia.
Abstract
Elevated serum cortisol associated with early‑detected increase of brain amyloid deposition in Alzheimer’s disease imaging biomarkers among menopausal women: The Framingham Heart Study
INTRODUCTION
This study examines whether serum cortisol measured in midlife predicts Alzheimer’s disease imaging biomarkers approximately 15 years later, with particular attention to sex differences and menopausal status.
METHODS
The analysis included 305 cognitively unimpaired participants from the Framingham Heart Study third‑generation cohort (48.5% female; mean age 39.6 ± 8.1 years). Baseline serum cortisol was divided into tertiles. Amyloid PET ([11C]PiB) and tau PET ([18F]Flortaucipir) imaging were performed about 15 years later. Multivariable regression models adjusted for potential confounders, including APOE4 status, were used to evaluate associations.
RESULTS
Higher midlife cortisol was associated with greater amyloid deposition in post‑menopausal women, especially in posterior cingulate, precuneus, and frontal‑lateral regions (p < 0.05). No significant relationships were found with tau burden or among male participants.
DISCUSSION
These findings indicate that women who have experienced menopause and who had elevated cortisol in midlife show greater subsequent amyloid accumulation, suggesting that menopausal hormonal changes may amplify cortisol’s adverse effects on brain amyloid pathology. The results underscore the importance of identifying modifiable risk factors in the preclinical phase and suggest avenues for stress‑reduction and hormone‑sensitive preventive strategies.